Serina Therapeutics, Inc.

Serina Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Huntsville, Alabama, on the campus of the HudsonAlpha Institute of Biotechnology. The company's core business revolves around its proprietary POZ Platform™ (poly(2-oxazoline) polymer technology), which aims to optimize drug delivery by enabling precise, controlled, and sustained drug exposure. This technology is designed to unlock the full potential of proven small molecule therapeutics, improving their performance in the body by extending delivery intervals, reducing side effects, and enhancing patient experience.

Serina Therapeutics develops a pipeline of drug candidates primarily targeting neurological diseases and pain. Its lead product candidate, SER-252 (POZ-apomorphine), is in a Phase 1b registrational trial for the treatment of advanced Parkinson's disease. The company is also developing SER-270 for Tardive Dyskinesia, which is anticipated to enter IND enabling studies, and SER-214 for early Parkinson's and Restless Leg Syndrome. Beyond these, Serina's POZ Platform™ is applied to POZ-lipids for lipid nanoparticle delivered RNA vaccines and is explored for applications in RNA medicines, cancer immunotherapy, and gene therapy through partnerships.

In recent news, Serina Therapeutics announced the FDA clearance of its IND application for SER-252 in January 2026, followed by the enrollment of the first patient in its Phase 1b registrational trial for advanced Parkinson's disease in February 2026. The company secured up to $30 million in private placement financing in March 2026 to advance this trial. In April 2026, the NYSE American accepted Serina's plan for continued listing compliance. Steve Ledger serves as the Chief Executive Officer, and Srini Tenjarla, Ph.D., was promoted to Chief Technology Officer in April 2026.